{"id":798893,"date":"2025-01-08T08:15:23","date_gmt":"2025-01-08T13:15:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\/"},"modified":"2025-01-08T08:15:23","modified_gmt":"2025-01-08T13:15:23","slug":"windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\/","title":{"rendered":"Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline"},"content":{"rendered":"

\nAll-Stock Acquisition Strategy Targets Multiple Small Companies with FDA-Approved Products to Drive Growth and Shareholder Value
\n<\/h2>\n
\n

WARRINGTON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (\u201cWindtree\u201d or the \u201cCompany\u201d) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has launched a new corporate strategy to become a revenue generating biotech company through acquisitions of small companies and their FDA-approved products while the Company continues to progress its cardiovascular and oncology development pipeline. The Company will seek acquisition targets to achieve the Company\u2019s new corporate strategy.<\/p>\n

Windtree believes there is an opportunity in the market: the acquisition of small companies with FDA-approved products from the many small biotech companies that struggle to maximize their commercialization potential. To capitalize on this opportunity, Windtree plans to become a parent company acquiring strategic subsidiaries with FDA-approved products. The Company’s management team has commercialization expertise in both large pharmaceutical and small biotech companies across multiple therapeutic areas, potentially enabling them to leverage synergies and optimize commercial performance across future subsidiaries.<\/p>\n

The Company will seek to use equity to acquire subsidiaries. The number of deals, if any, over time will depend upon the valuation and growth potential of the subsidiary companies.<\/p>\n

“We believe that Windtree becoming a revenue generating company would be a significantly positive transformation and would mark a new chapter in our growth story,” said Jed Latkin, CEO of Windtree. “By pursuing this strategy, we maintain our commitment to advance our promising cardiovascular and oncology pipeline while simultaneously leveraging our deep commercialization expertise to accelerate revenue growth through strategic acquisitions. This approach allows us to create near-term value through acquired commercial operations while preserving the potential of our development programs.”<\/p>\n

\n About Windtree Therapeutics, Inc.<\/strong>
\n
Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree\u2019s portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitor that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place.<\/p>\n

\n Forward Looking Statements<\/strong>
\n
Statements constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cproposed,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company\u2019s current expectations. Examples of such risks and uncertainties include, among other things: the Company\u2019s ability to acquire revenue generating subsidiaries; the market\u2019s reaction to potential acquisitions by the Company; the Company\u2019s ability to secure significant additional capital as and when needed; the Company\u2019s ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company\u2019s risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company\u2019s other product candidates, including preclinical oncology candidates; the Company\u2019s ability to access the debt or equity markets; the Company\u2019s ability to secure and successfully complete an out-licensing or asset acquisition transaction; the Company\u2019s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company\u2019s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company\u2019s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company\u2019s efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company\u2019s product candidates, and the Company\u2019s ability to service those markets; the Company\u2019s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company\u2019s product candidates, if approved; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People\u2019s Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and\/or other countries which could have an adverse impact on the Company\u2019s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company\u2019s ability to access the capital markets. These and other risks are described in the Company\u2019s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n

\n Contact Information:<\/strong>
\n
Windtree:
Eric Curtis
ecurtis@windtreetx.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

All-Stock Acquisition Strategy Targets Multiple Small Companies with FDA-Approved Products to Drive Growth and Shareholder Value WARRINGTON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (\u201cWindtree\u201d or the \u201cCompany\u201d) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has launched a new corporate strategy to become a revenue generating biotech company through acquisitions of small companies and their FDA-approved products while the Company continues to progress its cardiovascular and oncology development pipeline. The Company will seek acquisition targets to achieve the Company\u2019s new corporate strategy. Windtree believes there is an opportunity in the market: the acquisition of small companies with FDA-approved products from the many small … <\/p>\n

Continue reading “Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-798893","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nWindtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"All-Stock Acquisition Strategy Targets Multiple Small Companies with FDA-Approved Products to Drive Growth and Shareholder Value WARRINGTON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (\u201cWindtree\u201d or the \u201cCompany\u201d) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has launched a new corporate strategy to become a revenue generating biotech company through acquisitions of small companies and their FDA-approved products while the Company continues to progress its cardiovascular and oncology development pipeline. The Company will seek acquisition targets to achieve the Company\u2019s new corporate strategy. Windtree believes there is an opportunity in the market: the acquisition of small companies with FDA-approved products from the many small … Continue reading "Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-08T13:15:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODE1NSM2NjgzMzA5IzUwMDA3MzYyMA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline\",\"datePublished\":\"2025-01-08T13:15:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\\\/\"},\"wordCount\":1098,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODE1NSM2NjgzMzA5IzUwMDA3MzYyMA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\\\/\",\"name\":\"Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODE1NSM2NjgzMzA5IzUwMDA3MzYyMA==\",\"datePublished\":\"2025-01-08T13:15:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODE1NSM2NjgzMzA5IzUwMDA3MzYyMA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODE1NSM2NjgzMzA5IzUwMDA3MzYyMA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline - Market Newsdesk","og_description":"All-Stock Acquisition Strategy Targets Multiple Small Companies with FDA-Approved Products to Drive Growth and Shareholder Value WARRINGTON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (\u201cWindtree\u201d or the \u201cCompany\u201d) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has launched a new corporate strategy to become a revenue generating biotech company through acquisitions of small companies and their FDA-approved products while the Company continues to progress its cardiovascular and oncology development pipeline. The Company will seek acquisition targets to achieve the Company\u2019s new corporate strategy. Windtree believes there is an opportunity in the market: the acquisition of small companies with FDA-approved products from the many small … Continue reading \"Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-08T13:15:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODE1NSM2NjgzMzA5IzUwMDA3MzYyMA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline","datePublished":"2025-01-08T13:15:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\/"},"wordCount":1098,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODE1NSM2NjgzMzA5IzUwMDA3MzYyMA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\/","name":"Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODE1NSM2NjgzMzA5IzUwMDA3MzYyMA==","datePublished":"2025-01-08T13:15:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODE1NSM2NjgzMzA5IzUwMDA3MzYyMA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODE1NSM2NjgzMzA5IzUwMDA3MzYyMA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/windtree-therapeutics-announces-new-corporate-strategy-seeking-to-identify-and-acquire-fda-approved-revenue-assets-while-advancing-its-cardiovascular-and-oncology-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798893","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=798893"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798893\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=798893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=798893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=798893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}